Electronic Resource
DRUG DELIVERY RESEARCH ADVANCES
Ocular diseases such as age related macular degeration (AMD), diabetic retinopathy (DR), proliferative vitreal retinopathy (PVR), endopthlamitis and viral retinitis pose serious threat to vision if left untreated. The unique anatomy and physiology of eye offer many challenges to development of effective ocular drug delivery systems. Historically, drugs have been administered to the eye as simple drops instilled in the cul-de-sac. Recent advancements in the technology have led to the development of various polymeric ocular drug delivery systems such as biodegradable and nonbiodegradable implants, microspheres, nanoparticles, liposomes and gels. Due to continuous success, transporter and receptor targeted prodrug modification strategy is rapidly gaining acceptance in various drug delivery avenues. A novel strategy of circumventing efflux proteins (Pglycoprotein and multidrug resistance proteins) using transporter targeted drug delivery may improve specific targeting to cancer cells. Recent advances in biotechnology have resulted in the development of gene, antibody and nucleic acid therapy with significant activity against AMD, DR, PVR and viral retinitis. However, the attainment of therapeutic drug levels at the target site in a safe and effective manner for the desired length of time remains a major challenge. The diversity of the approaches for ocular drug delivery is an indication of the fact that the current ocular drug delivery approaches may not be optimal and further research may require for the successful development of ideal ocular drug delivery systems. This book chapter aims to delineate various challenges, opportunities and recent advances in the development of ocular drug delivery systems.
EBK-00214 | 615.6/Bor-d | Perpus Pusat | Tersedia |
Tidak tersedia versi lain